Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease

Susanne Ostrowitzki; Tobias Bittner; Kaycee M. Sink; Howard Mackey; Christina Rabe; Lawrence S. Honig; Emanuele Cassetta; Mark Woodward; Merçé Boada; Christopher H. van Dyck; Timo Grimmer; Dennis J. Selkoe; Andres Schneider; Kathleen Blondeau; Nan Hu; Angelica Quartino; David Clayton; Michael Dolton; Yifan Dang; Beth L. Ostaszewski; Sandra Sanabria Bohórquez; Michael Rabbia; Balázs István Tóth; Udo Eichenlaub; Jillian Smith; Lee Honigberg; Rachelle S. Doody

doi:10.1001/jamaneurol.2022.2909

Key Points

To assess the therapeutic safety and clinical efficacy of crenezumab compared with placebo in adults diagnosed with early Alzheimer disease.
Randomized, double-blind, placebo-controlled multicenter phase 3 clinical trials CREAD (NCT02670083) and CREAD2 (NCT03114657).
Adults with early Alzheimer disease were assigned to receive either regular infusions of crenezumab or matching placebo.
Trials assessed changes in cognitive decline and functional impairment using standardized dementia rating scales.
Safety evaluations monitored adverse events, including amyloid-related imaging abnormalities, across the treatment and placebo arms.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Randomized trial evaluates safety and efficacy outcomes of crenezumab in adults with early Alzheimer disease, highlighting targeted therapeutic strategies for slowing cognitive decline.

Abstract

ClinicalTrials.gov Identifiers: CREAD, NCT02670083; CREAD2, NCT03114657.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ostrowitzki et al. (2022) studied this question.

synapsesocial.com/papers/69dab5660f32475823a3d9da https://doi.org/10.1001/jamaneurol.2022.2909

View Full Paper

Ask AI

Bookmark

Share

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading